Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-7-14
|
| pubmed:abstractText |
2-Amino-1,4-dihydro-4-(2-[-4[4-(2-methoxyphenyl)-1-piperazinyl]- butylsulfinyl]phenyl)-6-methyl-5-nitro-3-pyridine carboxylic acid methyl ester (XB513) was designed to combine the calcium agonistic and alpha-1 adrenergic receptor antagonistic properties in the same molecule. It inhibited the specific binding of [3H] nitrendipine in rat cardiac ventricular membranes with an IC50 of 1.2 microM, which is 20-fold greater than the standard calcium agonist Bay K 8644. It displaced [3H]prazosin in rat brain membranes with an IC50 of 29 nM. XB513 caused concentration-dependent positive inotropic responses in isolated electrically paced guinea pig left atria with an EC50 of 1.2 microM and was 10 times less potent than Bay K 8644. In rabbit aorta, XB513 inhibited the contractile effect of 16 nM norepinephrine with an IC50 of 89 nM. In an acute heart failure dog model produced by an overdose of propranolol, XB513 at 0.3 to 3 mg/kg i.v. dose-dependently reversed the decreased mean arterial pressure, cardiac output and dP/dt as well as the increased left ventricular end diastolic pressure induced by propranolol. In conscious instrumented dogs, XB513 at 0.1 and 0.3 mg/kg i.v. increased dP/dt and heart rate significantly, with a minor effect on mean arterial pressure. In summary, this study demonstrates that XB513 is a novel chemical entity possessing both calcium agonistic and alpha-1 adrenergic receptor blocking properties and thus may represent a new class of agents for the treatment of congestive heart failure.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0022-3565
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
265
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1088-95
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8099616-Adrenergic alpha-Antagonists,
pubmed-meshheading:8099616-Animals,
pubmed-meshheading:8099616-Calcium Channel Agonists,
pubmed-meshheading:8099616-Dihydropyridines,
pubmed-meshheading:8099616-Dogs,
pubmed-meshheading:8099616-Female,
pubmed-meshheading:8099616-Guinea Pigs,
pubmed-meshheading:8099616-Heart,
pubmed-meshheading:8099616-Ileum,
pubmed-meshheading:8099616-Male,
pubmed-meshheading:8099616-Muscle Contraction,
pubmed-meshheading:8099616-Myocardial Contraction,
pubmed-meshheading:8099616-Piperazines,
pubmed-meshheading:8099616-Rabbits,
pubmed-meshheading:8099616-Radioligand Assay,
pubmed-meshheading:8099616-Rats,
pubmed-meshheading:8099616-Rats, Sprague-Dawley,
pubmed-meshheading:8099616-Structure-Activity Relationship
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Pharmacology of 2-amino-1,4-dihydro-4-(2-[4-[4-(2-methoxyphenyl)-1- piperazinyl]butylsulfinyl]phenyl)-6-methyl-5-nitro-3-pyridine carboxylic acid methyl ester (XB513), a novel calcium agonist with alpha-1 adrenergic receptor antagonistic.
|
| pubmed:affiliation |
Du Pont Merck Pharmaceutical Company, Wilmington, Delaware.
|
| pubmed:publicationType |
Journal Article,
In Vitro
|